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( WSSV specific sequence amplification) kit 
?C
First PCR PreMixreaction buffer, dNTPs, WSSV specific primers 
Nested PCR PreMixreaction buffer, dNTPs, WSSV specific primers 
(P+ standard)
(Yeast tRNA 40 ng/ l) 
DNA polymerase (2U/ l)
6X Loading dye 







(OD260 × 50 × reciprocal of dilution factor) / 1000 
DNA
DNA





























 TNTris-HCl 20 mM, NaCl 400 mM, pH 7.4




























OIE, Manual of Diagnostic Test for Aquatic Animals-2003, Nested polymerase chain reaction of tissues and 
haemolymph. 

































prewarmed elution buffer 8000 ×g , 1 min, room temperature
DNA
DNA
(OD260 × 50 × reciprocal of dilution factor) / 1000 
DNA
DNA
Concentration of DNA = (0.05 ×50 × 1000)/ 1000 = 2.5 g/ l
DNANested-PCR (IQ2000)First and Nested-PCR
TN TN Buffer
Tris-HCl 20 mM and NaCl 400 mM , pH= 7.4500Xg , 10 min, 
4 °C


















Lethal Dose50 (LD50)Van Hulten (2001b)
WSSVTN
g
Karber Formula:  
 -Log LD50 = Xa  D (Sp -0.5) 
Xa is the last dilution index for which all n cultures are infected (p=1) 
D is the log of the dilution factor (log 10 = 1) 
P is virus dilution proportion of infected cultures 
Sp is the summation of p between the last dilution for which all cultures are infected  (p=1) and the first dilution 
for which all n cultures are unaffected (p=0). 
Lethal Dose50 (LD50)Van Hulten (2001b)
WSSVTN
g
Karber Formula:  
-Log LD50 = Xa  D (Sp -0.5) 
Xa is the last dilution index for which all n cultures are infected (p=1) 
D is the log of the dilution factor (log 10 = 1) 
P is virus dilution proportion of infected cultures 
Sp is the summation of p between the last dilution for which all cultures are infected  (p=1) and the first dilution 
for which all n cultures are unaffected (p=0).  
WSSV
   MDS Nordion
4.8 Gy/sec20469 Ci
Standard Practice for Using the Fricke Reference-Standard Dosimetry System, E 1026 04e1 
















TCBS (Tiosulfat Citrate Bile Salt) 
Akhondzadeh Basti etal.,2007)
Skim MilkpH= 7.4
Colony Forming Unit (CFU)




























 10 9 CFU/ml
 International Commerce Corporation USA
GLYCOSAL COMPOSITION 
-Glucan(1,3-1,6) . % 30.0±3 
Mannanoligosacharides % 18.0±3  
BROMATOLOGICAL ANALYSIS 
Moisture ... Max. % 8.0 
Crude Protein ... % 32.0 
Ash .. Max. % 8.0 
pH Min. 5.0 
MINERALS: 
Calcium .. % 0.8 
Phosphorus . % 3.0 
Potassium % 1.1 
Magnesium . % 0.2 
Sodium % 2.0  
VITAMINS: 
Thiamine (B1) . ppm 71.1 
Riboflavin (B2) ppm 30.7 
Pyridoxine (B6) ppm 8.3 
Cobalamin (B12) . ppm 0.6 
Folic Acid ppm 11.2 
Biotin .. ppm 40.9


























DNA Ladeer (333, 630 and 848 bp)333 bp333 bp
333 bp333 bp
    
Nested PCR
333 bp




333 bp333 bp333 bp












IQ2000 (333- 630- 848 bp) 
1   2   3    4   5   6    7   8   9  10  11 12 13 14 15 16 17 18 19 
 DNA 
1   2           3    4    5    6     7   8    9   10  
nmnm
DMSO -20 °C-70 °C
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 Lethal Dose50 (LD50)Van Hulten (2001b)
Karber Formula:  
-Log LD50 = Xa  D (Sp -0.5) 
Xa is the last dilution index for which all n cultures are infected (p=1) 
D is the log of the dilution factor (log 10 = 1) 
P is virus dilution proportion of infected cultures 
Sp is the summation of p between the last dilution for which all cultures are infected  (p=1) and the first dilution 
for which all n cultures are unaffected (p=0).  
 
Proportion (P) 
Karber Formula:  
-Log LD50 = Xa  D (Sp -0.5) = -2-1 (1.85-0.5) = -3.35 
LD50 = 10 3.35/ 0.01 ml = 10 5.35 / ml 
Proportion (P) 
Karber Formula:  
-Log LD50 = Xa  D (Sp -0.5) = -1-1 (2.906-0.5) = -3.406 
LD50 = 10 3.4/ 0.01 ml = 10 5.4 / ml 







Karber Formula:  
-Log LD50 = Xa  D (Sp -0.5) = -2-1 (1.833-0.5) = -3.33 






Karber Formula:  
-Log LD50 = Xa  D (Sp -0.5) = 0-1 (2.159-0.5) = -1.659 
LD50 = 10 1.66/ 0.01 ml = 10 3.66 / ml 
    1      2      3     4       5       6      7      





Karber Formula:  
-Log LD50 = Xa  D (Sp -0.5) = 0-1(0.915-0.5)= -0.415 
LD50 = 10 0.415/ 0.01 ml = 10 2.415 / ml  
PCR
1                           2      3        4        5       6        
7
 




Karber Formula:  
-Log LD50 = Xa  D (Sp -0.5) = -0-1 (0.27-0.5) = 0.23 
LD50 = 10 -0.23/ 0.01 ml = 10 1.77 / ml 
PCR
DNA Ladder 




Karber Formula:  
-Log LD50 = Xa  D (Sp -0.5) = -0-1 (0.083-0.5) = 0.417 





Karber Formula:  
-Log LD50 = Xa  D (Sp -0.5) = -0-1 (0.083-0.5) = 0.417 
LD50 = 10 -0.417/ 0.01 ml = 10 1.58 / ml 































dose of gamma (kGy)




Y= 5.18- 0.39X 
5= 5.18- 0.39X  , X= 0.46 kGy 
2= 5.18- 0.39 x , X= 8.15 
8.15- 0.46= 7.69  , 7.69÷3= 2.563 kGy  D10 value  



















D ose o f e lectron (kG y)
dose su rv iva l cu rve
fitted line
Y= 4.72- 0.393 X 
5= 4.72- 0.393 X  , X= 0.71 
2= 4.72- 0.393 X  , X= 6.92 
6.92- 0.71=6.21 ÷3=2.07 kGy D10 value 





Karber Formula:  
-Log LD50 = Xa  D (Sp -0.5) =- 0-1(0.0-0.5) = -0.5 
LD50 = 10 -0.5/ 0.01 ml = 10 1.5 / ml 
TCBS (Tiosulfat Citrate Bile Salt) 
----- 
32+6+30=68 , 68/3= 22.6 × 108 = 2.26 × 108 = 2.3 × 108 
 CFU
 +  + +  = 
(8.62 ×109 )÷ 4 = 2.155 ×109 






FWI FI EB EWI EI GB GWI GI 
GI: Gamma-Immunogen, GWI: Gamma- without Immunogen, GB: Gamma-Bacteria, EI: Electron-Immunogen, 
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PD50
Reed and Muench method
(Reed & Muench, 1938)
Table 27 : Calculation of PD50% by Reed and Muench method for the inactivated 
WSSV-Vaccine by Gamma-irradiation without Immunogen. 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-28.5)/ (71.4-28.5) =21.5/43.2= 0.497 
(Log dilution below 50%) + (Pd × log dilution factor) =0.6+ (0.497 × 0.3) = 0.749 
PD50% for Radio-Vaccine=antilog 0.7495=5.61  
Table 28 : Calculation of PD50% by Reed and Muench method for the inactivated 
WSSV-Vaccine by Gamma-irradiation with Immunogen. 
Cumulative No % mortality 
Alive Dead 
Alive Dead Dilution 
0 18 0 5 0 1/1 
0 13 0 5 0 1/2 
0 8 0 5 0 1/4 
40 3 2 3 2 1/8 
100 0 7 0 5 1/16 
Cumulative No % mortality
Alive Dead 
AliveDeadDilution
0 15 0 5 0 1/1 
0 10 0 5 0 1/2 
28.5 5 2 3 2 1/4 
71.4 2 5 2 3 1/8 
 Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-40)/ (100-40) = 10/60= 0.16 
 (Log dilution below 50%) + (Pd × log dilution factor) =0.9+ (0.16 × 0.3) = 0.948 
PD50% for Radio-Vaccine=antilog 0.948= 8.87 
Table 29 : Calculation of PD50% by Reed and Muench method for the inactivated 
WSSV-Vaccine by Gamma-irradiation with inactivated Vibrio
Cumulative No % mortality 
Alive Dead 
Alive Dead Dilution 
0 19 0 5 0 1/1 
0 14 0 5 0 1/2 
0 9 0 5 0 1/4 
20 4 1 4 1 1/8 
100 0 6 0 5 1/16 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-20)/ (100-20) = 40/80= 0.2 
 (Log dilution below 50%) + (Pd × log dilution factor) =0.9+ (0.2 × 0.3) = 0.906 
PD50% for Radio-Vaccine=antilog 0.948= 8.05  
TN
102.4 LD50 / 50 l
PD50
Reed and Muench method5.626.02
6.30
Table 31 : Calculation of PD50% by Reed and Muench method for 
 the inactivated WSSV-Vaccine by Electron without Immunogen. 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50- 5 )/ ( -28.57) = 21.43/42.85= 0.5 
(Log dilution below 50%) + (Pd × log dilution factor) =0.6+ (0.5 × 0.3) = 0.75 
PD50% for Radio-Vaccine=antilog 0.75=5.62  
Table 32: Calculation of PD50% by Reed and Muench method for the inactivated 
WSSV-Vaccine by Electron with Immunogen. 
Cumulative No % mortality 
Alive Dead 
Alive Dead Dilution 
0 18 0 5 0 1/1 
0 13 0 5 0 1/2 
12.5 8 1 4 1 1/4 
75 4 3 3 2 1/8 
87.5 1 7 1 4 1/16 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-12.5)/ (75-12.5) = 37.5/62.5= o.6 
(Log dilution below 50%) + (Pd × log dilution factor) =0.6+ (0.6 × 0.3) = 0.78 
PD50% for Radio-Vaccine=antilog 0.78=6.02 
Table 33 : Calculation of PD50% by Reed and Muench method for 
 the inactivated WSSV-Vaccine by Electron with inactivated Vibrio 
Cumulative No % mortality 
Alive Dead 
Alive Dead Dilution 
0 16 0 5 0 1/1 
0 11 0 5 0 1/2 
14.28 6 1 4 1 1/4 
66.66 2 4 2 3 1/8 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-14.28/ (66.66- 14.28) = 35.72/52.38= 0.682 
 (Log dilution below 50%) + (Pd × log dilution factor) =0.6+ (0.682 × 0.3) = 0.8 






0 10 5 0 1/1 
0 10 5 0 1/2 
28.57 5 2 3 2 1/4 
71.42 2 2 3 1/8 
 TN
102.4 LD50 / 50 l
PD50
Reed and Muench method
Table 35: Calculation of PD50% by Reed and Muench method for  
the inactivated WSSV-Vaccine by formalin without Immunogen. 
Cumulative No % mortality 
Alive Dead 
Alive Dead Dilution 
0 16 0 5 0 1/1 
0 11 0 5 0 1/2 
16.66 6 1 4 1 1/4 
66.66 2 4 2 3 1/8 
 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-16.66)/ (66.66-16.66) =33.34/ 50= 0.6668 
(Log dilution below 50%) + (Pd × log dilution factor) =0.6+ (0.6668 × 0.3) = 0.8000 
PD50% for Radio-Vaccine=antilog 0.8000=6.30 
Table 36 : Calculation of PD50% by Reed and Muench method for  
the inactivated WSSV-Vaccine by formalin with Immunogen. 
Cumulative No % mortality 
Alive Dead 
Alive Dead Dilution 
0 18 0 5 0 1/1 
0 13 0 5 0 1/2 
12.5 8 1 4 1 1/4 
75 4 3 3 2 1/8 
87.5 1 7 1 4 1/16 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-12.5)/ ( -12.5) = 37.5/ = 0.
(Log dilution below 50%) + (Pd × log dilution factor) =0.6+ (0. × 0.3) = 0.7
PD50% for Radio-Vaccine=antilog 0.7 =
PD50%




















Reed and Muench method
Table38 : Calculation of PD50% by Reed and Muench method for  
the inactivated WSSV-Vaccine by Gamma-irradiation without Immunogen.
Cumulative No % mortality 
Alive Dead 
Alive Dead Dilution 
14.28 6 1 4 1 1/1 
66.66 2 4 2 3 1/2 
100 0 9 0 5 1/4 
100 0 14 0 5 1/8 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-14.28)/ (66.66-14.28) =35.72/52.38= 0.68 
(Log dilution below 50%) + (Pd × log dilution factor) =0+ (0.68 × 0.3) = 0.204 
PD50% for Radio-Vaccine=antilog 0.204= 1.6 
Table 39: Calculation of PD50% by Reed and Muench method for the 
 inactivated WSSV-Vaccine by Gamma-irradiation with Immunogen.
Cumulative No % mortality 
Alive Dead 
Alive Dead Dilution 
5.26 8 1 4 1 1/1 
33.33 4 2 4 1 1/2 
100 0 7 0 5 1/4 
100 0 12 0 5 1/8 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-33.33)/ (100-33.33) = 16.67/66.67= 0.250 
  (Log dilution below 50%) + (Pd × log dilution factor) =0.3+ (0.25 × 0.3) = 0.375 
PD50% for Radio-Vaccine=antilog 0.375= 2.37 
Table40 : Calculation of PD50% by Reed and Muench method for the 
 inactivated WSSV-Vaccine by Gamma-irradiation with inactivated Vibrio 
Cumulative No % mortality 
Alive Dead 
Alive Dead Dilution 
40 3 2 3 2 1/1 
100 0 7 0 5 1/2 
100 0 12 0 5 1/4 
100 0 17 0 5 1/8 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-40)/ (100-40) = 10/60= 0.16 
 (Log dilution below 50%) + (Pd × log dilution factor) =0+ (0.16 × 0.3) = 0.05 




Table 42 : Calculation of PD50% by Reed and Muench method for the inactivated 
WSSV-Vaccine by Electron without Immunogen. 
Cumulative No % mortality 
Alive Dead 
Alive Dead Dilution 
60 2 3 2 3 1/1 
100 0 8 0 5 1/2 
100 0 13 0 5 1/4 
100 0 18 0 5 1/8 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-0)/ (60 -0) = 0.833 
(Log dilution below 50%) + (Pd × log dilution factor) =0+ (0.833 × 0.3) = 0.249=0.25 
PD50% for Radio-Vaccine=antilog 0.25= 1.77  
Table 43: Calculation of PD50% by Reed and Muench method 
 for the inactivated WSSV-Vaccine by Electron with Immunogen. 
Cumulative No % mortality 
Alive Dead 
Alive Dead Dilution 
33.33 4 2 3 2 1/1 
85.71 1 6 1 4 1/2 
100 0 11 0 5 1/4 
100 0 16 0 5 1/8 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-33.33)/ (85.71- 33.33) = 16.67/ 52.38= 0.318 
(Log dilution below 50%) + (Pd × log dilution factor) =0+ (0.318 × 0.3) = 0.095 
PD50% for Radio-Vaccine=antilog 0.095= 1.244 
Table 44 : Calculation of PD50% by Reed and Muench method for 
 the inactivated WSSV-Vaccine by Electron with inactivated Vibrio 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-25)/ (83.33-25) = 25/ 58.33= 0.428 
 (Log dilution below 50%) + (Pd × log dilution factor) =0 + (0.428× 0.3) = 0.128 
PD50% for Radio-Vaccine=antilog 0.128= 1.34 
 
TN
Cumulative No % mortality
Alive Dead 
AliveDeadDilution
25 4 1 4 1 1/1 
83.33 1 5 1 4 1/2 
100 0 10 0 5 1/4 
100 0 15 0 5 1/8 
 105.4 LD50/ml
PD50
Table 46: Calculation of PD50% by Reed and Muench method for 
the inactivated WSSV-Vaccine by formalin without Immunogen. 
Cumulative No  % mortality 
Alive Dead 
Alive Dead Dilution 
16.66 5 1 4 1 1/1 
83.33 1 5 1 4 1/2 
100 0 10 0 5 1/4 
100 0 15 0 5 1/8 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-16.66)/ (83.33-16.66) =33.34/ 66.67= 0.50 
(Log dilution below 50%) + (Pd × log dilution factor) =0 + (0.50 × 0.3) = 0.15 
PD50% for Radio-Vaccine=antilog 0.15 = 1.41  
Table 47 : Calculation of PD50% by Reed and Muench method for
 the inactivated WSSV-Vaccine by formalin with Immunogen. 
Cumulative No  % mortality 
Alive Dead 
Alive Dead Dilution 
14.28 6 1 4 1 1/1 
66.66 2 4 2 3 1/2 
100 0 9 0 5 1/4 
100 0 14 0 5 1/8 
 
Proportion distance = (%50-%more dilution next below) / (%more dilution next abo-%more next below)  
Pd= (50-14.28)/ (66.66- 14.28) = 35.72/ 52.38= 0.682 
(Log dilution below 50%) + (Pd × log dilution factor) =0 + (0.682 × 0.3) = 0.204 
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The inactivated of white spot syndrome virus (WSSV) by Gama and Electron radiation and chemical material 
such as Formalin with antigen property have been done during last year. At the first time the stock of virus 
prepared and purred it. Six hundred of shrimp Fenneropenaus indicus with average weight 7 to 12 gram 
collected from shrimp research station in Heleh area and transported to Shrimp Research Institute in Boushehr 
province. Vibrio parahemolyticus obtained from Veterinary University of Tehran and then lyophilized it. The 
bacterial V. parahemolyticus inactivated with Gamma, electron and formalin and then injected to shrimp for 
activated the immune system.  The source of viruses was identified through PCR, TEM and histopathology 
methods from the shrimp infected in 2009 occurrence of boushehr province. The virus injected to crayfish and 
collected the hemlymph for prepared the stock of WSSV virus. The virus was lyophilized and then exposed to 
gamma and electron radiation and formalin with optimal dose for inactivated the virus. The shrimp divided to 25 
groups and each group consist of six shrimp and the vaccine exposed to shrimp with injected and bathroom 
methods and the documented the result after 15 days. In vivo virus titration was performed in Penaeus indicus. 
Inactivation of WSSV was carried out by a gamma cell instrument Nordian, model 220 with dose rate: 4.8 
Gy/sec and activity: 20469 Ci. The LD50 of live virus stock was calculated 10 5.4 / ml and the optimum dose of 
gamma radiation beam to inactivate WSSV was obtained 14-15 kGy. The LD50 of live virus stock was calculated 
10 5.4 / ml and the optimum dose of electron beam to inactivate WSSV was obtained 12-13 kGy and and the virus 
inactivated by formalin 0.5% V/V during 10 minutes.The LD50 of live virus stock was calculated by Karber 
method 10 3.29 /ml and 10 5.35 /ml, respectively. The V. parahemolyticus was inactivated with 8 KG. The result 
showed all vaccine during 2 hours have a good effect to shrimp viruses with the102.4 LD50 / 50 l titre. The result 
showed if the Gamma and electron vaccine increase to feed of shrimp the effect of vaccine is better than when 
used without feed. The end of experiment our study showed that the Gamma vaccine has the better effect to 
control WSSV during 2 hours with comparing the others. 
Key words: Vaccine, White Spot Syndrome Virus, Gamma Radiation, Electron Radiation, Formalin, Penaeus 
indicus.      
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